Dr. Laura M. Mclaughlin, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- Medical school
- Florida State University College of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: Florida State University College of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
AR license E-20538
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $19.58 in total to this clinician.
| Mesoblast, Inc. | $19.58 |
|---|
| Food and Beverage | $19.58 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $30,780 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open label, Single Arm, Multicenter Study of Ravulizumab in Pediatric Patients with Persistent Complement Mediated Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.